Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.43 |
| ▸ | HTR3A | P46098 | 5/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.41 |
| ▸ | CCR4 | P51679 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207835 | 0.84 | HRH4 (0.49) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL4206973 | 0.83 | HRH4 (0.53) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL4202001 | 0.82 | CTNNB1 (0.46) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL13780063 | 0.80 | HRH4 (0.51) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL4213585 | 0.78 | CCR4 (0.44) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL4209461 | 0.75 | HRH4 (0.42) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL4204592 | 0.74 | CCR4 (0.41) | HRH4HTR3APDE4APDE4BPDE4C | |
| SCHEMBL4324026 | 0.72 | CCR4 (0.42) | HRH4HTR3ACCR4 | |
| SCHEMBL4205164 | 0.70 | EPHX2 (0.43) | CCR4 | |
| SCHEMBL4207782 | 0.69 | EPHX2 (0.42) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | HRH4 3/4885HTR3A 1927/4885PDE4A 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.